Mean platelet volume and platelet count: overlooked markers of high on-treatment platelet reactivity and worse outcome in patients with acute coronary syndrome
Abstrakt
Acetylsalicylic acid and ADP inhibitor-based therapy is well established in coronary artery disease treatment. Despite this treatment, platelet reactivity may remain high in some patients.
Identification of risk factors associated with high on-treatment platelet reactivity is essential for rational antiplatelet treatment monitoring and for tailored antiplatelet treatment. The aim of the study was to assess the relationship between mean platelet volume, platelet count, platelet hematocrit and high on-treatment platelet reactivity in patients with acute coronary syndrome treated using percutaneous coronary intervention and its association with long-term mortality.
A cohort of 190 patients with acute myocardial infarction treated with acetylsalicylic acid and clopidogrel was enrolled in the study. We documented increased mean platelet volume, platelet count and platelet hematocrit in patients with high on-treatment platelet reactivity.
Mean platelet volume and platelet count were documented to be predictors of high on-treatment platelet reactivity. Three-year mortality was increased in patients with high mean platelet volume.